Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group-Reference-Cited by-同舟云学术

Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group

Published:2019-02-15 Issue:7 Volume:124 Page:662-670
ISSN:0033-8362
Container-title:La radiologia medica
language:en
Short-container-title:Radiol med

Author:

Borghetti Paolo,Bonù Marco Lorenzo,Giubbolini Rachele,Levra Niccolo’ Giaj,Mazzola Rosario,Perna Marco,Visani Luca,Meacci Fiammetta,Taraborrelli Maria,Triggiani Luca,Franceschini Davide,Greco Carlo,Bruni Alessio,Magrini Stefano Maria,Scotti Vieri

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/article/10.1007/s11547-019-00999-w/fulltext.html

Reference23 articles.

1. Burotto M, Manasanch EE, Wilkerson J, Fojo T (2015) Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 20(4):400–410. https://doi.org/10.1634/theoncologist.2014-0154

2. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S, Brahmer JR et al (2015) Systemic therapy for stage IV non-small-cell lung cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 33(30):3488–3515. https://doi.org/10.1200/JCO.2015.62.1342

3. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T et al (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390(10089):29–39. https://doi.org/10.1016/S0140-6736(17)30565-2

4. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM et al (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105(9):595–605. https://doi.org/10.1093/jnci/djt072

5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246. https://doi.org/10.1016/S1470-2045(11)70393-X

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complete and durable regression of leptomeningeal involvement during lorlatinib treatment in a patient with lung cancer;Anti-Cancer Drugs;2024-07-09

2. Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach;Exploration of Targeted Anti-tumor Therapy;2024-05-17

3. Radiotherapy in the management of lung oligometastases;Cancer/Radiothérapie;2024-02

5. From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC);Diagnostics;2023-12-25